Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

Daiichi Sankyo130 enrolled

Overview

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

130

Conditions

Essential Hypertension

Interventions

olmesartan medoxomilDRUG

olmesartan medoxomil oral tablets, once daily for up to 12 weeks

losartan potassiumDRUG

losartan oral tablets, once daily for up to 12 weeks

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diastolic BP 95 mm Hg - 114 mm Hg inclusive * No participation in any clinical trial for the last 3 months Exclusion Criteria: * Secondary hypertension * Malignant hypertension * Severe arterial hypertension * Significant cardiovascular disease * History or clinical evidence of cerebrovascular, gastrointestinal, hematological, hepatic disease, myocardial infarction, or severe liver disorder * Clinical evidence of renal disease, poorly controlled diabetes, known malabsorption syndromes, psychiatric/emotional problems

Locations (3)

Kaohsiung Medical University Hospital

Kaohsiung City, Taiwan

Chung Shun Medical University Hospital

Taichung, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Mean Change of Sitting dBP From Baseline to Week 12

The difference in the sitting diastolic blood pressure (dBP) at trough, i.e. 24±2 hours after drug administration, from base line to Week 12.

Time frame: Baseline to 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.